Caption: Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation (NYSE MKT:CVM) announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bos
Credit: Corporate Profile